Hormone modifying therapies, such as the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene decrease the risk of breast cancer or recurrence rate by blocking the effects of estrogen in breast tissue.3 Here, ESR1 is linked to breast cancer.